~187 spots leftby Mar 2034

Gantenerumab for Alzheimer's Disease

(DIAN-TU Trial)

Recruiting in Palo Alto (17 mi)
+35 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2 & 3
Recruiting
Sponsor: Washington University School of Medicine
Must not be taking: Immunosuppressives, Anticoagulants
Disqualifiers: Neurologic disease, Psychiatric disease, Stroke, Alcohol use, others
Prior Safety Data
Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you must be on stable doses of any non-excluded medications for at least 30 days before the trial starts. Some medications, like immunosuppressive drugs, are not allowed within 90 days before the trial.

What evidence supports the effectiveness of the drug gantenerumab for Alzheimer's disease?

Gantenerumab is a drug that targets and removes amyloid plaques in the brain, which are associated with Alzheimer's disease. Research suggests it has the potential to modify the disease by slowing or stopping its progression, similar to other anti-amyloid drugs like aducanumab, which has been approved for Alzheimer's treatment.12345

Is gantenerumab safe for humans?

Gantenerumab has been tested in clinical trials for Alzheimer's disease, and studies have looked at its safety, including how it is tolerated when injected under the skin. While the research focuses on Alzheimer's, it provides some information on safety in humans, such as the pain and tolerability of injections.13456

Research Team

EM

Eric M McDade, DO

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for adults over 18 with a genetic mutation linked to early onset Alzheimer's Disease (AD), or those with a 50% chance of having the mutation. Participants must be within certain years of expected symptom onset, have normal cognitive function, and agree to use contraception if applicable. Those already on stable medication can join, except for certain episodic treatments.

Inclusion Criteria

Informed consent form (ICF) is signed and dated by the participant and study partner, or by the participant's legally acceptable representative (LAR) if applicable, according to local regulations for the ICF and, if applicable, the DIAN-TU cognitive run-in (CRI) ICF and/or country-specific ICFs.
Participant is at least 18 years old.
Women of childbearing potential, if partner is not sterilized, must agree to use effective contraceptive measures (e.g., hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide) from Screening visit (V1) until 16 weeks after last dose of study drug.
See 7 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Stage 1 Treatment

Blinded placebo-controlled period to test if the study drug can slow, prevent, or reverse progression of Aβ pathology

208 weeks
Regular visits for biomarker and cognitive assessments

Stage 2 Treatment

Open-label period to assess the study drug's effect on non-amyloid biomarkers of AD

208 weeks
Regular visits for biomarker and cognitive assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Gantenerumab (Monoclonal Antibodies)
  • Matching Placebo (Gantenerumab) (Other)
Trial OverviewThe study tests Gantenerumab against a placebo in preventing or slowing amyloid beta accumulation in the brain, as seen by PET imaging. It also examines whether reducing amyloid plaques early affects AD progression by comparing biomarkers with an external control group.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Stage 1: RemternetugExperimental Treatment1 Intervention
Active Remternetug- blinded
Group II: Stage 2: Remternetug Open LabelActive Control1 Intervention
Open label will start after last dose of Stage 1
Group III: Stage 1: Matching Placebo (Remternetug)Placebo Group1 Intervention
Matching placebo

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

David H. Perlmutter

Washington University School of Medicine

Chief Executive Officer since 2015

MD from Washington University School of Medicine

Paul Scheel profile image

Paul Scheel

Washington University School of Medicine

Chief Medical Officer since 2022

MD from Washington University School of Medicine

Eli Lilly and Company

Industry Sponsor

Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky profile image

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks profile image

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University

Hoffmann-La Roche

Industry Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Alzheimer's Association

Collaborator

Trials
103
Recruited
44,300+

Dr. Joanne Pike

Alzheimer's Association

Chief Executive Officer since 2023

DrPH in Public Health Leadership from the University of North Carolina at Chapel Hill

Dr. Maria C. Carrillo

Alzheimer's Association

Chief Medical Officer

PhD in Neuroscience

National Institute on Aging (NIA)

Collaborator

Trials
1,841
Recruited
28,150,000+

Dr. Richard J. Hodes

National Institute on Aging (NIA)

Chief Executive Officer since 1993

MD from Harvard Medical School

Dr. Marie Bernard

National Institute on Aging (NIA)

Chief Medical Officer

MD from Harvard Medical School

Genentech, Inc.

Industry Sponsor

Trials
1,578
Recruited
569,000+
Ashley Magargee profile image

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

MBA from Harvard University, BA from Princeton University

Levi Garraway profile image

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2021

MD, PhD

Findings from Research

In a study of 1332 patients with Alzheimer's disease or other dementias in France, the prevalence of adverse drug reactions (ADRs) was found to be 5.0%, with serious ADRs occurring in 31.9% of cases, highlighting the potential risks associated with medication in this population.
The most common ADRs were gastrointestinal, central nervous system, and psychiatric disorders, with anti-dementia and psychotropic drugs being the most frequently implicated, indicating a need for careful monitoring and prescribing practices in patients with dementia.
Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study.Laroche, ML., Perault-Pochat, MC., Ingrand, I., et al.[2013]

References

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. [2019]
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. [2019]
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. [2021]
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. [2022]
A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers. [2020]
Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study. [2013]